WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck today announced a non-exclusive license agreement with Laboratory Corporation of America® Holdings (LabCorp®) for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus (HCV) infection to peginterferon alpha-based therapy.